Showing 1761-1770 of 4940 results for "".
- Gene Variants May Drive Persistent Lesions in Darier Diseasehttps://practicaldermatology.com/news/gene-variants-may-drive-persistent-lesions-darier-disease/2462509/Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and c
- LEO Foundation Plans to Double Philanthropic Grants for Skin Diseaseshttps://practicaldermatology.com/news/leo-foundation-plans-double-philanthropic-grants-skin-diseases/2462483/Reporting a successful year in 2023, the LEO Foundation has announced its goals and aspirations out to 2030, including the awarding of a prestigious 5 million Danish kroner prize to a distinguished researcher in Denmark contributing to skin research. The Foundation plans to double its phi
- Review: Lack of Specificity Seen in Outcome Measurement Instruments Used for AE Reporting in Cancer Trialshttps://practicaldermatology.com/news/outcome-measurement-instruments-used-to-evaluate-dermatologic-adverse-events-in-cancer-trials/2462443/Some common measurement instruments of patient-reported outcomes in skin cancer trials lack specificity and rigorous validation, according to a new systematic review. "Assessment of type, severity, and impact of dermatologic adverse events (DAEs) necessitates well-developed and validated
- Oxidative Stress Linked with Acne Severity: Analysishttps://practicaldermatology.com/news/circulating-biomarkers-of-oxidative-stress-in-acne-vulgaris/2462438/Biomarkers of oxidative stress correlated with the severity of acne vulgaris, according to a recent review published in the Archives of Dermatological Research. "The relationship between acne vulgaris and oxidative stress biomarkers lacks a clear consensus," the authors wrote. "
- New Data on Long-Term Efficacy of Nemolizumab in Prurigo Nodularis and Its Durability in ADhttps://practicaldermatology.com/news/new-data-on-long-term-efficacy-of-nemolizumab-in-prurigo-nodularis-and-its-durability-in-ad-1/2462433/Galderma announced new data demonstrating nemolizumab’s long-term and increasing efficacy on skin lesions and other symptoms in prurigo nodularis through to week 52 in the OLYMPIA LTE study.[1] Additionally, data from the ARCADIA 1 and 2 trials in atopic dermatitis indicate that the majority of p
- LEO Pharma Presents New Long-Term Adbry (Tralokinumab-ldrm) Data in Adults with Moderate-to-Severe ADhttps://practicaldermatology.com/news/leo-pharma-presents-new-long-term-adbry-tralokinumab-ldrm-data-in-adults-with-moderate-to-severe-ad/2462432/LEO Pharma unveiled new data analyzing the long-term therapeutic response of treatment with Adbry (tralokinumab-ldrm) in adults with moderate-to-severe atopic dermatitis (AD). The findings were shared via an e-poster at the 82nd American Academy of Dermatology (AAD) Congress in San Diego.[1]
- Lebrikizumab Linked with Improvement in Patients with AD and Skin of Colorhttps://practicaldermatology.com/news/lebrikizumab-linked-with-improvement-in-patients-with-atopic-dermatitis-and-skin-of-color/2462431/New first-of-its-kind research presented at the American Academy of Dermatology 2024 Annual Meeting suggests that lebrikizumab showed efficacy in patients with skin of color who had atopic dermatitis (AD). “People with skin of color are disproportionately affected by AD, often experienci
- Analysis: Alopecia Areata Linked with Work Productivity Losseshttps://practicaldermatology.com/news/analysis-alopecia-areata-linked-with-work-productivity-losses/2462430/Results from a new real-world analysis illuminated demographic and clinical characteristics associated with productivity losses in individuals with alopecia areata. “Patients with alopecia areata experience poor health-related quality of life and significant disease burden,” the authors w
- LITE: Home-based Narrow Band UVB Phototherapy for Psoriasis Non-Inferior to Office-based Treatmenthttps://practicaldermatology.com/news/lite-home-based-narrow-band-uv-b-phototherapy-for-psoriasis-noninferior-to-office-based-treatment/2462425/Home-based phototherapy for the treatment of psoriasis was non-inferior to office-based therapy, according to new data presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. Researchers for the Light Treatment Effectiveness (LITE) study, looking at whether home
- Alumis Closes $259 Million Financing to Help Launch Phase 3 Psoriasis Trial for Lead Asset ESK-001https://practicaldermatology.com/news/alumis-closes-259-million-financing-to-help-launch-phase-3-psoriasis-trial-for-lead-asset/2462267/In this year's largest privite biotech fundraise to date, Alumis announced $259 million Series C financing to initiate pivotal phase 3 clinical trials for its lead candidate ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe pl